SHENZHEN, CHINA - China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that the New Drug Application (NDA) in China for the Seasonal Allergic Rhinitis (SAR) indication of MG-K10 (generic name: Comekibart Injection, “MG-K10” or the “Product”), a Class 1 innovative drug anti-IL-4Rα humanized monoclonal antibody injection, for which the Group holds co-development rights (excluding the indication of atopic dermatitis (AD)) and exclusive commercialization rights, was accepted by the National Medical Products Administration of China (NMPA) on 23 April 2026.

The global digital finance sector is entering a structural transition that analysts increasingly describe as a shift from speculative markets to institutional infrastructure.

CGTN examines the resilience of China-Vietnam “comrades-plus-brothers” ties, highlighting how high-level exchanges sustain strategic trust. It also outlines growing cooperation in trade, infrastructure and youth exchanges, as both sides advance the building of a higher-level China-Vietnam community with a shared future that carries strategic significance amid global uncertainties.

“We bathe in the same river. I look over there, you look over here. Every day, we hear the rooster crow together.”

People to People exchange creates an environment… making it easier for our political leaders to come together.

 – Judy Hoarfrost – Ping Pong Diplomat